TXG Stock Recent News

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Results continue to indicate high-grade mineralization and the long-term potential of the deposit (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide remaining results from the 2024 drilling program and initial results from the 2025 drilling program at ELG Underground. The results support the Company's target of further extending the mine life of ELG Underground by identifying new zones of higher-grade mineralization, expanding resources within known areas, and replacing mined reserves.

PLEASANTON, Calif. , May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies.

The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Cassie Corneau – Senior Director, Investor Relations Serge Saxonov – Chief Executive Officer and Co-Founder Adam Taich – Chief Financial Officer Conference Call Participants Patrick Donnelly – Citi Kyle Mikson – Canaccord Genuity Madeline Mollman – Wolfe Research Matt Sykes – Goldman Sachs Kyle Boucher – TD Cowen Operator Ladies and gentlemen, thank you so much for standing by and welcome to 10x Genomics First Quarter 2025 Earnings Conference Call. Please note that this call is being recorded.

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

10x Genomics (TXG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.

PLEASANTON, Calif. , May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025.

Results in line with expectations and tracking well to full-year guidance (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 7, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three months ended March 31, 2025. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.

Milestone marks the Company's official transition to become both a gold and copper producer (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 1, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to announce it has achieved commercial production at the Media Luna mine, concluding the development phase of the Media Luna Project. Amongst other criteria, commercial production is declared when construction is substantially complete, mine and mill throughput have averaged over 40% and 60% of design rates for 30 days, respectively, product is saleable, and metallurgical recoveries have averaged at least 60% of the design recovery levels.